• ALK-Abelló named Jacob Glenting executive vice president, head of Global R&D, effective Sept. 1, 2026.
• The role has been vacant since February 2026.
• Glenting is currently EVP, Corporate, Portfolio & Product Strategy, a post he has held since joining the executive leadership team in 2024.
• His background includes more than 25 years in pharmaceuticals, business development, research, a PhD in vaccine development and immunology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200133OMX_____CNEWS_EN_GNW1001258450_en) on August 20, 2026, and is solely responsible for the information contained therein.